Share This Page
Patent: 9,821,051
✉ Email this page to a colleague
Summary for Patent: 9,821,051
| Title: | Reducing hospitalization in elderly influenza vaccine recipients |
| Abstract: | Compared to an unadjuvanted vaccine, an adjuvanted influenza vaccine can reduce by almost a quarter the risk of hospitalization for respiratory illness (e.g. influenza and pneumonia) in elderly recipients. Thus the invention provides a method for immunizing an elderly subject by administering an adjuvanted influenza vaccine, whereby the subject\'s risk of hospitalization for respiratory illness (e.g. influenza and pneumonia) is reduced relative to an elderly subject who receives an unadjuvanted influenza vaccine. |
| Inventor(s): | Groth; Nicola (Siena, IT) |
| Assignee: | Seqirus UK Limited (Berkshire, GB) |
| Application Number: | 13/279,156 |
| Patent Claims: | see list of patent claims |
| Patent landscape, scope, and claims summary: | Executive summary US 9,821,051 is a method-of-use patent focused on vaccinating elderly humans (≥65) across multiple consecutive influenza seasons with split-virus, inactivated seasonal influenza antigens where the adjuvanted arm uses a specific oil-in-water (O/W) emulsion adjuvant system (notably squalene and surfactant combinations) and yields reduced pneumonia/influenza hospitalization vs an unadjuvanted split-virus comparator. The claim set is layered to progressively narrow adjuvant composition (squalene; polysorbate 80/sorbitan trioleate; or polyoxyethylene sorbitan monooleate/sorbitan trioleate), emulsion droplet size (sub-220 nm; ranges such as 100–250 nm; at least 90% <200 nm), formulation characteristics (purified surface antigen in later dependent claims), administration route (intramuscular), and population selection and vaccination regimen constraints (no crossover to unadjuvanted vaccine in specified seasons; in claim 18 excludes recent hospitalization/nursing home/rehab/home care). From a competitive and litigation standpoint, the enforceability and practical “design-around” hinge on (i) whether a competitor’s product uses the same split-virus antigen approach and emulsion droplet profile, (ii) whether the adjuvant chemistry matches the recited surfactant matrix (including specific O/W emulsion ingredients), and (iii) whether clinical benefit is framed/used in a way that reads on the claimed hospitalization-reduction method rather than purely on an immunogenicity claim. Infringement exposure is highest for products using MF59-like squalene-based O/W submicron emulsions with the specific surfactant pairing recited and used in elderly multi-season seasonal immunization schemes, especially if promotional or study design aligns with pneumonia/influenza hospitalization endpoints. US Patent 9,821,051 claims analysis: adjuvanted split-virus influenza vaccination in elderly across consecutive seasonsUS 9,821,051 claim 1 establishes the independent method claim; claims 2–13 and 14–22 carve dependent limitations around formulation composition, emulsion droplet size, antigen type, route, and population eligibility. What does independent claim 1 cover (and what it does not)?Claim 1 core elements (method of immunization):
Claim 1 does not expressly require:
Legal consequence for claim scopeClaim 1 is broad on “adjuvanted vaccine” concept but narrow on:
A competitor that uses a different antigen processing approach (eg, whole virion or subunit without “split virus antigen” characterization) can avoid at least one core limitation even if it uses an MF59-like adjuvant. Which dependent claims lock the adjuvant system into a narrow emulsion specification?Claims 5–13 progressively specify the adjuvant. Oil-in-water emulsion adjuvant (claims 5–10)
Key point: these dependent claims define multiple possible adjuvant embodiments. A competitor may try to avoid infringement by selecting an MF59-like adjuvant that does not match the precise surfactant set in a particular asserted dependent claim. But note that infringement analysis can choose which dependent limitation is triggered; a plaintiff typically asserts the tightest-fitting claim family to match the accused product’s composition. Droplet size constraints (claims 11–13)
Design-around leverage: emulsion droplet size distributions are measurable by dynamic light scattering and related methods. If an accused adjuvant uses larger droplets or a different distribution profile, it can avoid droplet-size-dependent limitations. If it still meets “<220 nm” but fails “≥90% <200 nm,” claim coverage narrows to the applicable dependent claim asserted. What do claims 2–4 do to limit product comparability and administration route?
Why it matters: claim 2 and 3 establish a “like-for-like” comparator structure, strengthening the causality narrative for hospitalization reduction vs unadjuvanted baseline. If a competitor uses different antigen amounts/strains or substantially reformulates the antigen/excipients beyond adding adjuvant, it can potentially evade the dependent structure even if efficacy appears similar. What does claim 14 add: purified surface antigen + tetravalent + specific emulsion recipe?Claim 14 is an independent-like expansion via a dependent path from claim 1 (as written, it is an additional independent claim in the patent):
Claim 14 narrows the adjuvant to the exact surfactant pair in claim 10 and requires “purified surface antigen” framing. Many marketed influenza vaccines for older adults are not described in promotional materials as “purified surface antigen,” so the phrasing matters for claim construction and infringement proof. What does claim 18 add: three seasons + strict prior-care exclusion?Claim 18 is a further expansion with additional eligibility constraints:
Population selection effect: This exclusion can be a litigation lever. A real-world older-adult target population often includes high fractions with recent care. If an accused program includes such residents or home care patients, a defendant can argue mismatch with claim 18’s pre-immunization status constraints. How many claims in US 9,821,051 depend on droplet size and the emulsion recipe?Droplet-size-dependent coverage appears in:
Emulsion recipe dependency appears in:
In practice, claim coverage is strongest for products that match the exact surfactant pair and meet the submicron droplet thresholds called out. What patents protect adjuvanted influenza vaccination in elderly with oil-in-water squalene emulsions?US 9,821,051 sits in a crowded adjuvanted-influenza landscape dominated by squalene-based O/W emulsions and by clinical data used to support hospitalization endpoints. Key adjacent patent families (by subject matter) typically include:
Critical point: the claim language here is unusually specific about:
That combination usually narrows the universe of infringing products more than generic “use of an adjuvant for influenza” patents. How do these claims compare with typical adjuvant influenza method patents?Common patterns in method-of-use influenza adjuvant patents include:
US 9,821,051 shifts toward:
This can strengthen the argument against broad novelty-destroying prior art that focuses on immunogenicity rather than hospitalization endpoints, but also raises proof burdens tied to trial design, endpoints, and population selection. What is the Orange Book status of US 9,821,051?US 9,821,051 is a method-of-use patent and typically would not list in the Orange Book as a “drug product” patent by itself unless it is listed by the NDA holder for a specific NDC. Method claims may or may not be Orange Book listed depending on the NDA labeling and listing strategy. No Orange Book status can be asserted from the claim text alone. When does US 9,821,051 lose exclusivity (patent expiration timeline)?A deterministic expiration timeline requires:
No expiration computation can be produced from claim text alone. Which generic or biosimilar entry risks exist for US 9,821,051?Influenza vaccines are small-molecule-adjacent in the sense they are chemically distinct biologics category products, and the “generic” model does not apply cleanly. For vaccines, risk usually flows through:
The most realistic “entry risk” is for next-generation or biosimilar-like competitors using different adjuvants or different antigen processing. The patent is best read as a composition-plus-method lock. How strong is the patent estate for US 9,821,051 (claim robustness and vulnerabilities)?Robustness levers for the patentee
Vulnerabilities for enforcement
What patent litigation strategy typically follows US 9,821,051 claims?For method patents like this, enforcement typically targets:
If a defendant product uses a different adjuvant recipe (different surfactants) or a different antigen processing description, the patentee’s infringement narrative must rely on claim 1 rather than the narrower dependents, or pursue product-specific claim mapping. Claim-by-claim infringement mapping checklist (accused product alignment)For infringement under claim 1:
For infringement under claims 5–13:
For infringement under claims 14 and 18 (strongest product-specific locks):
Key Takeaways
FAQs1) Does US 9,821,051 require a specific influenza strain list to infringe? 2) Can a competitor avoid infringement by using a different squalene emulsion surfactant system? 3) Is droplet size a major validity or enforcement battleground for US 9,821,051? 4) Does the patent cover both trivalent and tetravalent influenza vaccines? 5) Are the claimed endpoints limited to pneumonia and influenza hospitalization only? References
More… ↓ |
